Physician profile
Sandhya P Desai
NPI 1790703775
$5,842.13
in general payments reported to CMS, 2019-2025
35 companies · $616 in 2025
The $616 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $683 · 2020: $778 · 2021: $1,313 · 2022: $976 · 2023: $766 · 2024: $710 · 2025: $616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,091.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $876.63 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $715.11 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $613.21 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $510.93 | 2019-2025 | Jardiance, Synjardy |
| Amgen INC. | $453.64 | 2019-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals LP | $436.08 | 2019-2023 | Breztri |
| Esperion Therapeutics, INC. | $253.60 | 2020-2024 | Nexletol |
| Lilly USA, LLC | $229.95 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $220.21 | 2019-2025 | |
| Amarin Pharma, INC. | $201.46 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $198.52 | 2019-2024 | |
| Arbor Pharmaceuticals, INC. | $181.97 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $115.64 | 2019-2024 | Eliquis |
| Abbvie INC. | $113.78 | 2019-2025 | |
| Dexcom, INC. | $111.91 | 2022-2025 | Dexcom G6 Transmitter |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandhya Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.